Brain Region-Specific Neural Spheroids for High-Throughput Disease Modeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models for neurological diseases, such as stem-cell derived neuronal organoids, face challenges in high-throughput systems due to long maturation times, variable size and functionality, and lack of reproducibility, making them unsuitable for efficient disease modeling and therapeutic testing.
Innovation Solution
Development of brain region-specific spheroids comprising specific ratios of neurons and glial cells, such as GABAergic, glutamatergic, and dopaminergic neurons, and astrocytes, which are cultured to exhibit electrophysiological and calcium activity profiles similar to defined brain regions, allowing for controlled and reproducible modeling of neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem-cell derived neuronal organoids are used for disease modeling, then physiological relevance is improved, but maturation time increases significantly
Solution Approach 1:
The patent applies preliminary action by pre-differentiating neural progenitor cells into specific neuronal subtypes and glial cells before spheroid formation. This advance preparation of cell types with defined characteristics enables the spheroids to achieve functional maturity faster, reducing the overall maturation time while maintaining physiological relevance.
Solution Approach 2:
The patent implements local quality by creating spheroids with specific regional compositions of neurons and glial cells that mirror particular brain regions. By concentrating appropriate cell types in defined ratios within each spheroid, the model achieves localized physiological accuracy without requiring full-brain organoid development, thereby reducing maturation time.
2Manufacturing precision
If cerebral and patterned brain organoids are developed to maturity, then tissue-like architecture is improved, but production time increases to weeks or months
Solution Approach 1:
The patent applies segmentation by dividing the complex brain tissue architecture into discrete spheroid units, each containing specific neuronal and glial cell compositions. This segmentation allows parallel production of multiple standardized spheroids simultaneously, dramatically increasing productivity while maintaining consistent tissue-like architecture through controlled cell ratios and spheroid sizes.
Solution Approach 2:
The patent utilizes parameter changes by optimizing cell density, spheroid size, and neuronal-to-glial cell ratios to achieve mature tissue-like architecture more rapidly. By adjusting these parameters during culture, the system accelerates structural development without sacrificing architectural fidelity, reducing production time from weeks/months to a more efficient timeframe.
3Ease of manufacture
If traditional organoid protocols are used, then cell differentiation is achieved, but reproducibility and robustness deteriorate due to variable size and cell composition
Solution Approach 1:
The patent implements universality by developing a standardized spheroid protocol that can be applied across multiple brain region models. The universal framework specifies precise cell type ratios, spheroid formation conditions, and culture parameters that ensure consistent differentiation outcomes. This standardized approach enables reproducible generation of various brain region-specific spheroids using the same core methodology, enhancing both robustness and reproducibility.
4Reliability
If in vivo animal models are used for neurological disease research, then disease modeling capability is improved, but throughput decreases significantly
Solution Approach 1:
The patent applies copying by creating simplified three-dimensional spheroid models that replicate key features of in vivo brain tissue and disease pathology. These spheroid copies maintain essential disease-relevant cellular interactions and physiological properties while being amenable to high-throughput culture and screening, thereby achieving both disease modeling fidelity and increased productivity compared to whole animal models.
Data Source
AI summary
Functional, brain region-specific neural spheroids comprising neuronal cells and optionally glial cells at varying ratios are disclosed, as are methods of making such spheroids and methods for their use, such as for modeling particular brain regions that may be implicated in diseases, or for observing drug effects.